Quantcast
0
0
Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers - 90% of subjects had reduction of free IgE to below the limit of detection by the end of XmAb7195 infusion, including at lowest dose evaluated of 0.3 mg/kg -- Dose limiting toxicity of thrombocytopenia observed at 3.0 mg/kg -- Enrollment continues in Part 2 of trial for high IgE subjects -- Conference call today at 8:30 a.m. ET -
$
X
Sharing:
Title:
URL:
Copy Share URL